{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:22:19Z","timestamp":1790486539105,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,15]]},"DOI":"10.2146\/ajhp150281","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T10:13:12Z","timestamp":1459764792000},"page":"547-555","source":"Crossref","is-referenced-by-count":21,"title":["Idelalisib for treatment of B-cell malignancies"],"prefix":"10.1093","volume":"73","author":[{"given":"Bryan","family":"Do","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Mace","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Rexwinkle","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102514571900_b1-0730547","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t2019041102514571900_b2-0730547","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102514571900_b3-0730547","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b4-0730547","unstructured":"National Cancer Institute. FDA approval for idelalisib (2014July29). www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-idelalisib (accessed 2014 Oct 20)."},{"key":"key\n\t\t\t\t2019041102514571900_b5-0730547","volume-title":"Zydelig (idelalisib) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041102514571900_b6-0730547","first-page":"1855","volume-title":"Cancer principles & practice of oncology","author":"DeVita","year":"2011","edition":"9th ed"},{"key":"key\n\t\t\t\t2019041102514571900_b7-0730547","first-page":"3909","article-title":"The non-Hodgkin\u2019s lymphoma classification project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b8-0730547","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","article-title":"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center","volume":"25","author":"Tsimberidou","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b9-0730547","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b10-0730547","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphoma, version 1 (2015). www.nccn.org (accessed 2015 Jan 9)."},{"key":"key\n\t\t\t\t2019041102514571900_b11-0730547","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40265-013-0092-5","article-title":"The optimal management of follicular lymphoma: an evolving field","volume":"73","author":"Ujjani","year":"2013","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019041102514571900_b12-0730547","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b13-0730547","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11899-012-0142-1","article-title":"GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia","volume":"8","author":"Macias-Perez","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"key\n\t\t\t\t2019041102514571900_b14-0730547","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b15-0730547","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","article-title":"Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia","volume":"18","author":"Herman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041102514571900_b16-0730547","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2005-07-3041","article-title":"Key role of the p110\u03b4 isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110\u03b4 function in B cells","volume":"107","author":"Bilancio","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b17-0730547","doi-asserted-by":"crossref","first-page":"850.10(suppl)","DOI":"10.1096\/fasebj.26.1_supplement.850.10","article-title":"Biotransformation of GS-1101 (CAL-101), a potent and selective inhibitor of PI3K delta for the treatment of patients with hematologic malignancies","volume":"26","author":"Chen","year":"2012","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t2019041102514571900_b18-0730547","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102514571900_b19-0730547","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b20-0730547","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1182\/blood.V122.21.5054.5054","article-title":"Exposure-response of idelalisib, a novel PI3K\u03b4 inhibitor, administered as monotherapy in the treatment of hematologic malignancies","volume":"122","author":"Zhou","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b21-0730547","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/blood.V122.21.5570.5570","article-title":"Pharmacokinetics, metabolism, and excretion of idelalisib","volume":"122","author":"Robeson","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b22-0730547","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1182\/blood.V122.21.5572.5572","article-title":"The pharmacokinetics and safety of idelalisib with severe renal impairment","volume":"122","author":"Robeson","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b23-0730547","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/blood.V122.21.5571.5571","article-title":"The pharmacokinetics and safety of idelalisib with moderate or severe hepatic impairment","volume":"122","author":"Robeson","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b24-0730547","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1200\/jco.2011.29.15_suppl.6631","article-title":"Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia","volume":"29","author":"Coutre","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b25-0730547","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/jco.2013.31.15_suppl.7003","article-title":"Final results of a phase I study of idelalisib (GS-1101), a selective inhibitor of PI3K\u03b4, in patients with relapsed or refractory CLL","volume":"31","author":"Brown","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b26-0730547","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b27-0730547","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/jco.2013.31.15_suppl.7017","article-title":"Update on a phase I study of the selective PI3K\u03b4 inhibitor idelalisib (GS-1101) in combination with rituximab and\/or bendamustine in patients with relapsed or refractory CLL","volume":"31","author":"Barrientos","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b28-0730547","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102514571900_b29-0730547","volume-title":"Idelalisib plus bendamustine and rituximab (BR) in superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study","author":"Zelenetz"},{"key":"key\n\t\t\t\t2019041102514571900_b30-0730547","doi-asserted-by":"crossref","volume-title":"Idelalisib monotherapy and durable responses in patients with relapsed or refractory small lymphocytic lymphoma (SLL)","author":"Gopal","DOI":"10.1182\/blood.V126.23.2743.2743"},{"key":"key\n\t\t\t\t2019041102514571900_b31-0730547","doi-asserted-by":"crossref","volume-title":"Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)","author":"Martin","DOI":"10.1182\/blood.V126.23.1543.1543"},{"key":"key\n\t\t\t\t2019041102514571900_b32-0730547","first-page":"1","volume-title":"Mantle cell lymphoma facts","year":"2014"},{"key":"key\n\t\t\t\t2019041102514571900_b33-0730547","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102514571900_b34-0730547","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041102514571900_b35-0730547","volume-title":"Redbook Online [online database]"},{"key":"key\n\t\t\t\t2019041102514571900_b36-0730547","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019041102514571900_b37-0730547","unstructured":"Gilead Sciences, Inc. Zydelig AccessConnect (2015). www.zydeligaccessconnect.com\/ (accessed 2015 Feb 19)."},{"key":"key\n\t\t\t\t2019041102514571900_b38-0730547","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2011.1.110","article-title":"The treatment of relapsed refractory chronic lymphocytic leukemia","volume":"2011","author":"Brown","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t2019041102514571900_b39-0730547","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102514571900_b40-0730547","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/jco.2013.31.15_suppl.7005","article-title":"A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K\u03b4) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) \u226565 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","volume":"31","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102514571900_b41-0730547","unstructured":"ClinicalTrials.gov . Study to investigate idelalisib in combination with chemotherapeutic agents, immunomodulatory agents and anti-CD20 monoclonal antibody (mAb) in subjects with relapsed or refractory indolent B-cell non-Hodgkin\u2019s lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01088048 (accessed 2015 Feb 20)."},{"key":"key\n\t\t\t\t2019041102514571900_b42-0730547","unstructured":"ClinicalTrials.gov . Safety and efficacy of idelalisib in relapsed or refractory Hodgkin lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01393106 (accessed 2015 Feb 20)."},{"key":"key\n\t\t\t\t2019041102514571900_b43-0730547","unstructured":"ClinicalTrials.gov . Study of phosphatidylinositol-3-kinase (PI3K) inhibitor idelalisib (GS-1101) in Waldenstr\u00f6m macroglobulinemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439138 (accessed 2016 Jan 14)."},{"key":"key\n\t\t\t\t2019041102514571900_b44-0730547","unstructured":"ClinicalTrials.gov . Study of single agent idelalisib followed by idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02468557 (accessed 2016 Jan 14)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/8\/547\/28335352\/ajhp0547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:58:30Z","timestamp":1655427510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/8\/547\/5101723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,4,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150281","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4,15]]},"published":{"date-parts":[[2016,4,15]]}}}